KERYDIN (tavaborole) · ANACOR PHARMS INC
KERYDIN is FDA-approved to treat 1 condition (same as TAVABOROLE).
Details
- Status
- Discontinued
- First Approved
- 2014-07-07
- Routes
- TOPICAL
- Dosage Forms
- SOLUTION
KERYDIN Approval History
What KERYDIN Treats
1 indicationsKERYDIN is approved for 1 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Onychomycosis
Same approved indications as TAVABOROLE (same active ingredient).
ANACOR PHARMS INC's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KERYDIN FDA Label Details
Indications & Usage
FDA Label (PDF)KERYDIN is FDA-approved to treat 1 condition — same approved indications as TAVABOROLE.
Track KERYDIN with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.